ATE234090T1 - Kombination von duloxetin mit nichtsteroid- entzündungshemmern für die behandlung von schmerz - Google Patents

Kombination von duloxetin mit nichtsteroid- entzündungshemmern für die behandlung von schmerz

Info

Publication number
ATE234090T1
ATE234090T1 AT99960277T AT99960277T ATE234090T1 AT E234090 T1 ATE234090 T1 AT E234090T1 AT 99960277 T AT99960277 T AT 99960277T AT 99960277 T AT99960277 T AT 99960277T AT E234090 T1 ATE234090 T1 AT E234090T1
Authority
AT
Austria
Prior art keywords
duloxetine
pain
treatment
combination
inflammatory drugs
Prior art date
Application number
AT99960277T
Other languages
English (en)
Inventor
Smriti Iyengar
Carrie Kimberly Jones
Harlan Edgar Shannon
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of ATE234090T1 publication Critical patent/ATE234090T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Processing Of Meat And Fish (AREA)
AT99960277T 1998-11-13 1999-11-10 Kombination von duloxetin mit nichtsteroid- entzündungshemmern für die behandlung von schmerz ATE234090T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10837098P 1998-11-13 1998-11-13
PCT/US1999/026655 WO2000028980A2 (en) 1998-11-13 1999-11-10 Combination of duloxetine with non-steroidal antiinflammatory drug for treating pain

Publications (1)

Publication Number Publication Date
ATE234090T1 true ATE234090T1 (de) 2003-03-15

Family

ID=22321828

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99960277T ATE234090T1 (de) 1998-11-13 1999-11-10 Kombination von duloxetin mit nichtsteroid- entzündungshemmern für die behandlung von schmerz

Country Status (9)

Country Link
US (1) US6245802B1 (de)
EP (1) EP1135121B1 (de)
JP (1) JP2002529499A (de)
AT (1) ATE234090T1 (de)
AU (1) AU1718400A (de)
CA (1) CA2350531A1 (de)
DE (1) DE69905938T2 (de)
ES (1) ES2194536T3 (de)
WO (1) WO2000028980A2 (de)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6586458B1 (en) * 1996-08-16 2003-07-01 Pozen Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
US8022095B2 (en) 1996-08-16 2011-09-20 Pozen, Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
JP2003530437A (ja) * 2000-04-13 2003-10-14 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ Ａβ４２低下物質
MY120279A (en) * 2000-05-26 2005-09-30 Pharmacia Corp Use of a celecoxib composition for fast pain relief
DK1313697T3 (da) 2000-08-29 2006-04-10 Nobex Corp Immunregulatoriske forbindelser, derivater deraf samt anvendelse deraf
AU2001285334A1 (en) * 2000-08-29 2002-03-13 Peter Van Patten Combination for the treatment of migraine comprising a cyclooxygenase-2 inhibitor and acetylsalicylic acid
US6528076B2 (en) 2001-07-06 2003-03-04 Magic Herb Corp. Topical compositions and methods for treating pain
US8048924B2 (en) * 2001-08-29 2011-11-01 Biocon Limited Methods and compositions employing 4-aminophenylacetic acid compounds
CA2479350A1 (en) * 2002-03-15 2003-09-25 Cypress Bioscience, Inc. Ne and 5-ht reuptake inhibitors for treating visceral pain syndromes
CN1662231A (zh) * 2002-04-24 2005-08-31 柏树生物科学公司 包括应激相关障碍在内的功能性躯体障碍的预防与治疗
AU2003229408A1 (en) 2002-06-10 2003-12-22 Philippe Kriwin Oral antidepressant formulation comprising a selective serotonin_reuptake inhibitor
US20100189797A1 (en) * 2002-06-10 2010-07-29 Julien Mendlewicz Oral antidepressant formulation
US20040235925A1 (en) * 2002-12-17 2004-11-25 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of duloxetine, venlafaxine or atomoxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
GB0229583D0 (en) * 2002-12-19 2003-01-22 Cipla Ltd A process for preparing duloxetine and intermediates for use therein
ES2380827T3 (es) * 2002-12-26 2012-05-18 Pozen, Inc. Formas de dosificación con múltiples capas que contienen naproxeno y triptanes
WO2004071431A2 (en) * 2003-02-05 2004-08-26 Myriad Genetics, Inc. Method and composition for treating neurodegenerative disorders
KR20060015641A (ko) * 2003-06-06 2006-02-17 글락소 그룹 리미티드 트립탄 및 ｎｓａｉｄ를 포함하는 조성물
KR20060040676A (ko) * 2003-07-11 2006-05-10 미리어드 제네틱스, 인크. 알츠하이머병을 치료하기 위한 약제학적 방법, 투약 방법및 제형
ES2332176T3 (es) * 2003-10-29 2010-01-28 Philippe Kriwin Formulacion antidepresiva oral que contiene un acido acetilsalicilico para acelerar su accion.
WO2005051378A1 (en) * 2003-11-21 2005-06-09 Myriad Genetics, Inc. Method and composition for treating neurodegenerative disorders
WO2006001877A2 (en) * 2004-04-13 2006-01-05 Myriad Genetics, Inc. Combination treatment for neurodegenerative disorders comprising r-flurbiprofen
AU2005241023A1 (en) * 2004-04-29 2005-11-17 Keystone Retaining Wall Systems, Inc. Veneers for walls, retaining walls and the like
EP2933332A1 (de) 2004-06-28 2015-10-21 The University Of Western Australia Antisense-oligonukleotide zur induktion von exon-skipping sowie verfahren zur verwendung davon
DK1773767T3 (en) 2004-07-07 2016-03-21 Biocon Ltd Synthesis of azo bound in immune regulatory relations
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
BRPI0514303A (pt) * 2004-08-11 2008-06-10 Myriad Genetics Inc composição farmacêutica e método para tratar distúrbios neurodegenerativos
US8093408B2 (en) * 2005-06-21 2012-01-10 The Company Wockhardt Antidepressant oral pharmaceutical compositions
US8153824B2 (en) * 2005-06-22 2012-04-10 The Wockhardt Company Antidepressant oral liquid compositions
WO2007005644A2 (en) * 2005-07-01 2007-01-11 Concert Pharmaceuticals Inc. Novel aryloxypropanamines
CA2615063A1 (en) * 2005-07-22 2007-02-01 Myriad Genetics, Inc. High drug load formulations and dosage forms
US20060165776A1 (en) * 2005-08-31 2006-07-27 Ramesh Sesha Antidepressant oral pharmaceutical compositions
WO2007062119A1 (en) * 2005-11-23 2007-05-31 Auspex Pharmaceuticals, Inc. Substituted aryloxypropylamines with serotoninergic and/or norepinephrinergic activity
WO2007134168A2 (en) * 2006-05-10 2007-11-22 Dr. Reddy's Laboratories Ltd. Process for preparing duloxetine
WO2008006099A2 (en) * 2006-07-07 2008-01-10 Myriad Genetics, Inc. Treatment of psychiatric disorders
WO2008009665A1 (en) * 2006-07-19 2008-01-24 Boehringer Ingelheim International Gmbh Treatment of pain
US20090162421A1 (en) * 2007-12-21 2009-06-25 Paz Arzneimittel-Entwicklungsgesellschaft Mbh Drugs as well as their production and use in the treatment of pain-associated neuropathies
MX2010006608A (es) * 2007-12-21 2010-10-05 Paz Arzneimittelentwicklung Composiciones farmaceuticas y produccion y uso de las mismas en el tratamiento de neuropatias asociadas con el dolor.
EP2123626A1 (de) * 2008-05-21 2009-11-25 Laboratorios del Dr. Esteve S.A. Duloxetin-Kokristalle und Kokristallbildner für Schmerzbehandlung
BR122020021379B1 (pt) 2008-10-24 2021-05-11 Sarepta Therapeutics, Inc. oligômero morfolino fosforodiamidato, composição que compreende o mesmo e uso do dito oligômero para tratar distrofia muscular
TR201816523T4 (tr) 2009-11-12 2018-11-21 Univ Western Australia Patolojilerin tedavisine yönelik antisens moleküller ve yöntemler.
EP2332930A1 (de) * 2009-11-23 2011-06-15 Laboratorios Del. Dr. Esteve, S.A. Salze von Duloxetin und NSAIDs zur Behandlung von Schmerz
AU2012205733B2 (en) 2011-01-11 2015-10-08 Signature Therapeutics, Inc. Compositions comprising enzyme-cleavable oxycodone prodrug
JP6148182B2 (ja) 2011-03-09 2017-06-14 シグネーチャー セラピューティクス, インク.Signature Therapeutics, Inc. 複素環式リンカーを有する活性薬剤プロドラッグ
WO2012122420A2 (en) 2011-03-09 2012-09-13 Pharmacofore, Inc. Opioid prodrugs with heterocyclic linkers
US9855286B2 (en) 2012-05-18 2018-01-02 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-di methyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a salicylic acid component
US20130310435A1 (en) 2012-05-18 2013-11-21 Gruenenthal Gmbh Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N, N-dimethyl-4-phenyl-4,9' -dihydro-3'H-spiro[cyclohexane-1,1' -pyrano[3,4,b]indol]-4-amine and Paracetamol or Propacetamol
US9320729B2 (en) 2012-05-18 2016-04-26 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-flouro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a propionic acid derivative
US20130310385A1 (en) 2012-05-18 2013-11-21 Gruenenthal Gmbh Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine and Antidepressants
RU2506077C1 (ru) * 2013-01-25 2014-02-10 Общество С Ограниченной Ответственностью "Валента-Интеллект" Комбинация для профилактики, коррекции и терапии боли, связанной с нейродегенерацией или ассоциированной с соматоформными расстройствами
CN110218727A (zh) 2013-03-14 2019-09-10 萨勒普塔医疗公司 用于治疗肌营养不良的外显子跳跃组合物
US20140329762A1 (en) 2013-03-15 2014-11-06 Sarepta Therapeutics, Inc. Compositions for treating muscular dystrophy
HRP20220112T1 (hr) 2013-12-24 2022-04-15 Virginia Commonwealth University Upotreba oksidacijskog sulfata kolesterola (ocs) za liječenje akutne insuficijencije jetre
IL305493A (en) 2021-03-09 2023-10-01 Ensysce Biosciences Inc Compositions comprising enzyme-cleavable prodrugs and controlled release nafamostat and methods of use thereof
CA3230025A1 (en) 2021-09-29 2023-04-06 Lynn Kirkpatrick Enzyme-cleavable methadone prodrugs and methods of use thereof
CN114404409A (zh) * 2022-02-23 2022-04-29 江苏海洋大学 一种可治疗疼痛的药物组合及其应用
US20250186455A1 (en) * 2023-12-07 2025-06-12 Taghogho Agarin Treatment composition for treating chronic pain and mixed pain sites

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0906104A4 (de) * 1996-03-25 2003-12-10 Lilly Co Eli Schmerzbehandlungsverfahren
WO1998046227A1 (en) * 1997-04-11 1998-10-22 Eli Lilly And Company Composition for treating pain
AU7247898A (en) * 1997-04-11 1998-11-11 Eli Lilly And Company Composition for treating pain
US5942530A (en) * 1997-08-28 1999-08-24 Eli Lilly And Company Method for treating pain

Also Published As

Publication number Publication date
DE69905938D1 (de) 2003-04-17
WO2000028980A2 (en) 2000-05-25
DE69905938T2 (de) 2003-11-13
AU1718400A (en) 2000-06-05
EP1135121B1 (de) 2003-03-12
EP1135121A2 (de) 2001-09-26
US6245802B1 (en) 2001-06-12
JP2002529499A (ja) 2002-09-10
CA2350531A1 (en) 2000-05-25
WO2000028980A3 (en) 2000-07-27
ES2194536T3 (es) 2003-11-16

Similar Documents

Publication Publication Date Title
ATE234090T1 (de) Kombination von duloxetin mit nichtsteroid- entzündungshemmern für die behandlung von schmerz
EA200100572A1 (ru) Способ применения ингибитора циклооксигеназы-2 и одного или нескольких противоопухолевых лекарственных средств в качестве комбинированного способа лечебного воздействия при лечении неоплазии
ATE279919T1 (de) Agmatin für die behandlung neuropathischer schmerzen
FI970101A0 (fi) Uusi farmaseuttinen valmiste kivun hallintaan
ATE207352T1 (de) Nicht-allosterische gaba a agonisten zur behandlung von schlafstörungen
PT971713E (pt) Utilizacao de inibidores da colinesterase para tratamento de desordens da atencao
DE69805202D1 (de) Verwendung von benzhydrylsulfinylderivaten zur behandlung der schläfigkeit medikamentösen ursprungs
DE69841574D1 (de) Gaba-analoga zur verhütung und behandlung gastrointestinaler beschwerden
ATE350030T1 (de) Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
ATE512163T1 (de) Verabreichung von mitteln zur behandlung von entzündungen
DE69941949D1 (de) topische ZUSAMMENSETZUNGEN enthaltend einen alpha 1-adrenergic blocker ZUR BEHANDLUNG VON SCHMERZHAFTEN ZUSTÄNDEN DER ANALREGION
TR200000755T2 (tr) Karşıt olma-karşı gelme bozukluğunun tedavisi.
PT1173201E (pt) Metodo para o tratamento de fibrose utilizando um antagonista da subunidade alfa 4 de integrina
EP1098642A4 (de) Verfahren zur behandlung von zustanden moduliert durch lactosylceramiden
EP1781277A4 (de) Kombinationspräparat
DE69711078D1 (de) Topische verwendung von kappa-opioidrezeptoragonisten zur behandlung von augenschmerz
CO4940456A1 (es) Metodo antiinflamatorio
ATE223721T1 (de) Edelfosin zur behandlung von hirntumoren
ATE322898T1 (de) Inhibitoren von mycobakterien
EE9700350A (et) COMT-inhibiitorite uus kasutamine ja diabeetiliste vaskulaarsete häirete ärahoidmise meetod
DE60006284D1 (de) Arzneimittel zur behandlung konvulsivischer zustände
ATE236633T1 (de) Topische verwendung von loperamid zur behandlung mikrobieller infektionen
ATE369143T1 (de) Verwendung von ngali nussöl zur behandlung/linderung der arthritisschmerzen und anderer ähnlichen störungen
ATE244010T1 (de) Arzneistoffkombination zur behandlung von kopfschmerzen mit mirtazapine und paracetamol oder nicht-steroiden entzündungshemmenden mitteln
DE69635282D1 (de) Behandlung der exzessiven aggressivität mit olanzapine

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties